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ABSTRACT
The proportion of different microbial populations in gut microbiota (GM) is an important factor that in
recent years has been linked to obesity and numerous metabolic diseases. Antibiotics are one of the
factors that can dramatically alter GM at therapeutic dosages, but their effects at subtherapeutic doses
have been less investigated. Here, a mousemodel using a total of 60 C57BL/6J mice was used to compare
the evolution of total microbiota, four phyla and two genera considered as probiotics in control mice, and
mice exposed to 50 µg/kg of ampicillin, 100 µg/kg of tetracycline or 100 µg/kg of sulphadiazine. The
results obtained found that the presence of antibiotics in foods, even at trace concentrations,
can disturb mouse GM, causing in all antibiotics significant increases of Proteobacteria (about
2 log CFU/g) or decreases of Bifidobacterium and Lactobacillus (about 1 log CFU/g) for the
cases of ampicillin and sulphadiazine.
La ingesta de bajas dosis de antibióticos es capaz de alterar la microbiota
intestinal en ratones
RESUMEN
La composición de las diferentes poblaciones microbianas presentes en la microbiota intestinal
humana es un aspecto importante que en los últimos años ha sido relacionada tanto con la
obesidad con como muchas patologías metabólicas. Los antibióticos son uno de los agentes que
pueden alterar de manera radical la composición de la microbiota intestinal cuando se utilizan a
dosis terapéuticas, pero sus efectos a dosis sub-terapéuticas han sido menos investigados. Para este
fin, se ha realizado un ensayo empleando 60 ratones C57BL/6J para comparar la evolución de la
microbiota total, así como 4 filos y 2 géneros bacterianos beneficiosos en ratones control, ratones
expuestos a 50 µg/kg de ampicilina, ratones expuestos a 100 µg/kg de tetraciclina y ratones
expuestos a 100 µg/kg de sulfadiacina. Los resultados obtenidos mostraron que la presencia de
antibióticos en los alimentos, incluso a concentraciones traza, pueden alterar la microbiota intestinal
de los ratones, causando todos los antibióticos un incremento significativo de Proteobacteria
(aproximadamente 2 log ufc/g), o descensos en los géneros Bifidobacterium y Lactobacillus (aprox-
imadamente 1 log ufc/g) en los casos de la ampicilina y la sulfadiacina.
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The human digestive tract is colonized by trillions of microbes,
collectively termed gut microbiota (GM) that comprise
approximately 1012 colony-forming units/mL in the colon and
can influence gastrointestinal physiology as well as the function
of distant organs of the host (Fröhlich et al., 2016). This ecosys-
tem can be readily modified by multiple factors, including the
genotype and immunity of the host, environmental influences,
diet or the use of therapeutic agents (Cox & Blaser, 2015).
In recent years, it has been demonstrated that GM play an
important role in human health, with a relevant influence in
obesity, diabetes, metabolic syndrome, cancer, cardiovascular
diseases or even in psychiatric disorders (Conlon & Bird, 2015;
Roca-Saavedra et al., 2018). Regarding the relation of GM to
obesity, it has been reported that alteration in the popula-
tions of the GM may change intra-community metabolic
interactions, modify caloric intake by using carbohydrates
such as cellulose that are otherwise indigestible by the host
and globally affect host metabolic, hormonal and immune
homeostasis (Conlon & Bird, 2015). More recently, it has
been reported that imbalance in GM can result in a pro-
inflammatory luminal environment that can contribute to
the progression of low-level chronic inflammation and meta-
bolic disorders (Roca-Saavedra et al., 2018).
One factor that can dramatically affect GM composition and
function is the effect of antibiotics. Epidemiological studies have
confirmed the positive relationship, especially at early ages,
between antibiotic use and weight gain in humans and indicate
that even prenatal antibiotic exposure predisposes to childhood
overweight (Cox & Blaser, 2015; Korpela & de Vos, 2016).
Additionally, it has been reported that associations between
obesity and exposure to antibiotics are different depending on
the antibiotic spectrum (Mikkelsen, Allin, & Knop, 2016), subject
age (Cox & Blaser, 2015; Korpela & de Vos, 2016) and even
between boys and girls (Azad, Bridgman, Becker, & Kozyrsky,
2014; Mikkelsen et al., 2016).
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Antibiotic use has reached enormous proportions around
the world, although it is not consistent across geographical
areas and countries (Nobel et al., 2015). However, little atten-
tion has been paid to the potential effect of subtherapeutic
doses that can reach humans (Roca-Saavedra et al., 2018).
Based on this matter, Ternak (2005) was the first to propose
that human exposure to low-dose antibiotics may contribute
to weight gain in humans. Since the 1940s, farmers have
added low doses of antibiotics to the food or water of live-
stock to promote growth of farm animals (Nobel et al., 2015).
Even in the European Union (EU, 2003), in which antibiotics
are banned to act as growth promoters (EC Regulation 1831/
2003), the use of antibiotics in veterinary medicine is com-
mon. As a consequence, antibiotic residues can reach
humans at low concentrations through the food supply
chain or through drinking water (Andersson & Hughes,
2014; Cox & Blaser, 2015).
In addition to livestock sources, antimicrobial agents are
released into the environment from aquaculture, spraying of
fruit orchards and vegetables, and from discarded expired
drugs, hospital effluents and other human activities. Thus,
there is ample evidence that antibiotics can enter our food
chain from a variety of sources, that humans are chronically
exposed to these drugs (Riley, Raphael, & Faerstein, 2013).
Considering this common exposure of humans to low
dosages of antimicrobials, mainly carried by foods, the aim
of the present work was to investigate the effects of low
dosages of antimicrobials carried by foods at concentrations
allowed by European Union Regulation 37/2010 for human
consumption on the GM of mice (EU, 2010a).
Materials and methods
Animals and treatments
Sixty female C57BL/6J mice were obtained at 8 weeks of age
from the Universidade de Santiago de Compostela central
animal facility and allowed to adjust to the Lugo animal
facility for a week for adaption to the new environment.
Mice were weighed at the beginning of the experiment
and distributed five per cage so that mean weights in each
cage were similar. Each study group (control or antibiotic)
was composed of 15 mice (3 cages of 5 mice) which were
maintained at stable light conditions (12 h light/dark cycle),
maximal light intensity (100 lx), temperature (set point 22°C)
and relative air humidity (set point 50%) and a controlled
cycle of filtered ventilation.
Throughout the experiments, tap water and standard
laboratory chow were provided ad libitum. Because it was
reported, possible alterations in ingestion have been
reported if antibiotics are administered via the drinking
water (Fröhlich et al., 2016) and antibiotics were adminis-
tered mixed into feed. Mice received Harlan Global Diet 2018
S (Harlan Laboratories, Madison, WI, USA) mixed to contain
50 µg/kg of ampicillin, 100 µg/kg of sulphadiazine, 100 µg/
kg of tetracycline or no antibiotics (control) for 16 weeks.
The antibiotics employed were chosen on the basis that
tetracyclines (tetracycline), β-lactams (ampicillin) and sulpho-
namides (sulphadiazine) are those most employed for veter-
inary purposes in Europe (Grave et al., 2014). Dosages were
chosen as the maximum residue limits allowed in the
European Union for meat and/or milk destined for human
consumption by European Union Regulation 37/2010.
Antibiotics employed for mixing with the feed (ampicillin
sodium salt, catalogue number A9518, sulphadiazine catalo-
gue number S8626 or tetracycline catalogue number T3258)
were obtained from Sigma-Aldrich (St. Louis, MO, USA).
The experimental procedures and number of animals
used were approved by the Institutional Animal Care and
Use Committee of Xunta de Galicia (Authorization Code
MR110250) and conducted according to the Directive of
the European Parliament and the Council of 22 September
2010 (EU, 2010b). The experiments were designed in such a
way that animal suffering was minimized.
Each week, the mice were serially weighed on an electro-
nic scale tared between all measurements. Because of their
coprophagic behaviour, all cage batches received the same
treatment. Feed was changed once daily to supply fresh
antibiotics.
Collection of stool samples and DNA extraction
Stool samples were collected twice a week in a sterile
container (10–30 g/cage) using sterilized surgical material
and anaerobiosis condition generated using a GENbox sys-
tem (GENbox, Biomérieux, Marcy L’Etoile, France) and were
treated within 2 h of collection. DNA extraction consisted of
a first step in a 1:10 dilution of phosphate-buffered saline
(Invitrogen, Paisley, UK) adjusted to pH 7.2–7.4, and subse-
quent homogenization in a Masticator® (AES, Counbourg,
France) for 5 min. Samples were afterwards frozen until use,
and DNA extraction was performed using 1 mL of each
sample using a commercial kit (Realpure Microspin, Durviz
S., Valencia, Spain), as was previously employed in recent
works (Castro-Penalonga et al., 2018; Rodriguez-Costa et al.,
2018). Following this protocol, stool samples were diluted
in isolation buffer, vortex-agitated and incubated at 80°C
for 30 min. Afterwards, samples were centrifuged at
14,000 rpm for 10 min. Pellets were taken, placed in micro-
tubes and diluted with 600 µL of binding buffer and 20 µL
of proteinase K. The mix was vortex-agitated and then
incubated at 70°C for 10 min, when 300 µL of isopropanol
was added and mixed. After this, the lysates were pipetted
into a special flask and centrifugated at 12,000 rpm for 60 s
to obtain pellets. Afterwards, the pellets were washed with
disinhibition buffer, wash buffer and elution buffer, follow-
ing the volumes and centrifugation times established by
the manufacturer’s instructions to obtain genomic DNA.
Bacterial quantification by real-time PCR from faecal
samples
A real-time quantitative PCR (qPCR) procedure was used for the
quantification of the bacterial groups investigated in human
faecal samples by using specific primers based on previously
reported methods (Murri et al., 2013) (Table 1). Thus, the first
step consisted of a denaturation step at 95°C for 10min and was
followed by 45 denaturation cycles at 95°C for 10 s and an
elogation step for 1 min at the temperature optimal for each
bacterial group. Finally, analysis of the obtained curves (0.05°C
per cycle) was performed bymeasurement of the intensity of the
Syber Green® fluorochrome (Applied Biosystems, Foster City,
CA, USA), according to previously reported by Guarddon et al.
(2011). All reactions were carried out in triplicate, the final
volume being 20 mL and containing 2 mL of DNA and a con-
centration of 100 nM of each of the probes. PCR amplifications
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were performed using ABI PRISM 7000 equipment (Applied
Biosystems, Warrington, UK) associated ABI PRISM 7000
Software (Applied Biosystems). Reference strains employed for
the standard curves were Enterobacter cloacae CECT 194,
Clostridium perfringens CECT 376, Bifidobacterium longum CECT
4503, Bacteroides vulgatus LMG 17767 and Lactobacillus reuteri
DSMZ 20016 (Table 1). All strains were grown in liquid medium
under their optimal growth conditions and decimal dilutions
were made for subsequent plate-counting. Once counted, the
DNA was extracted from the tube, and the DNA was quantified
by fluorescence using a Qubit Fluorometer (Invitrogen, Oregon,
USA). Each of the curves was normalized to the copy number of
the 16S rRNA gene for each of the species. For species for which
the copy number of the 16S rRNA operonwas not published, the
copy number was calculated by averaging the operon numbers
of the closest bacterial taxa from the ribosomal RNA database
rrnDB (Rodriguez-Costa et al., 2018). Negative controls contain-
ing all the elements of the reaction mixture except template
DNA were performed in every analysis and no product was ever
detected. The data presented are the mean values of triplicate
real-time qPCR analyses.
Statistical analysis
The bacterial data obtained from mice faeces were
expressed as log10 CFU/g faeces average values obtained
and their corresponding standard deviations. The results
obtained for mice weights and the different bacterial
populations studied were compared among the different
population groups by means of analysis of variance.
Weight gain and feed efficiency were compared by means
of Student’s t-test. In all cases, the differences obtained were
considered statistically significant for a level of significance
of P < 0.05. All statistical analyses were performed using
SPSS 20.0 software (SPSS Inc., Chicago, IL, USA).
Results and discussion
After 16 weeks of exposure of mice to control or antibiotic-
mixed feed, the observed weights were within the expected
range of growth for female C57BL/6J mice. In accordance
with previous works (Cho et al., 2012), there were no sig-
nificant differences in overall weight between control mice
and mice exposed to tetracycline or sulphadiazine, while a
smaller weight gain increase was found for mice exposed to
ampicillin (P = 0.034) (Table 2). Additionally, as was pre-
viously found by Cho et al. (2012), there were no significant
differences in calculated feed efficiency, expressed as weight
gained per unit of feed consumed, between the treated and
control mice.
As can be seen in Table 3, the evolution of total
microbiota in the control subjects was quite stable
throughout the study period, oscillating between values of
11 and 11.5 log CFU/g faeces. These values are compatible
with those previously published by other authors, both for
the total microbiota of mice (Okubo et al., 2013) and of
humans (Aurumugan et al., 2011).
In all cases, after administration of the antibiotic (either
ampicillin, sulphadiazine or tetracycline), evolution of the
total GM of mice exposed to antibiotics was statistically
different to that of the controls (P > 0.001) (Table 3). In this
way, after the administration of all antibiotics, there was an
Table 1. Bacterial species-specific primers and reference strains employed for real-time PCR.
Tabla 1. Cebadores específicos y cepas de referencia empleados para la PCR en tiempo real.
Target Primer sequence (5′-3′) Reference strain Product size (bp)
Total microbiota F: ACTCCTACGGGAGGCAGCAG
R: ATTACCGCGGCTGCTGG
Clostridium perfringens CECT 376 200
Firmicutes F: ATGTGGTTTAATTCGAAGCA
R: AGCTGACGACAACCATGCAC
Clostridium perfringens CECT 376 126
Bacteroidetes F: CATGTGGTTTAATTCGATGAT
R: AGCTGACGACAACCATGCAG
Bacteroides vulgatus LMG 17767 126
Actinobacteria F: GCGKCCTATCAGCTTGTT
R: CCGCCTACGAGCYCTTTACGC
Bifidobacterium longum CECT 4503 333
Proteobacteria F: CATGACGTTACCCGCAGAAGAAG
R: CTCTACGAGACTCAAGCTTGC
Enterobacter cloacae CECT 194 195
Bacteroides F: GAGAGGAAGGTCCCCCAC
R: CGCTACTTGGCTGGTTCAG
Bacteroides vulgatus LMG 17767 106
Bifidobacterium spp. F: CTCCTGGAAACGGGTGG
R: GGTGTTCTTCCCGATATCTACA
Bifidobacterium longum CECT 4503 550
Lactobacillus spp. F: AGCAGTAGGGAATCTTCCA
R: CACCGCTACACATGGAG
Lactobacillus reuteri DSMZ 20016 341
CECT: Spanish Type Culture Collection; DSMZ: German Collection of Microorganisms and Cell Cultures; LMG: Bacteria Collection Laboratorium voor Microbiologie
Universiteit Gent.
CECT: Colección Española de Cultivos Tipo; DSMZ: Colección Alemana de Microorganismos y Cultivos Celulares; LMG: Colección Bacteriana del Laboratorio de
Microbiología de la Universidad de Gent.
Table 2. Initial weight, final weight and weight increase of control and exposed to antibiotics mouse.
Tabla 2. Peso inicial, peso final e incremento de peso en los ratones controles y expuestos a los antibióticos.
Day 0 4 weeks 8 weeks 12 weeks 16 weeks Weight gain/feed efficiency
Control 18.43 ± 1.06 19.83 ± 0.98 21.56 ± 1.24 23.23 ± 1.43 23.83 ± 1.21a 5.4 ± 0.42a/0.019 ± 0.02a
Ampicillin 18.93 ± 0.93 20.12 ± 0.89 21.63 ± 0.99 23.43 ± 0.93 24.04 ± 1.48a 5.11 ± 0.24b/0.018 ± 0.04a
Sulphadiazine 18.56 ± 1.30 19.86 ± 1.23 21.21 ± 1.35 22.94 ± 1.30 24.06 ± 1.29a 5.5 ± 0.37a/0.020 ± 0.03a
Tetracycline 18.41 ± 1.25 19.76 ± 1.21 21.89 ± 1.42 23.54 ± 1.25 23.94 ± 1.37a 5.53 ± 0.31a/0.021 ± 0.03a
Results are expressed as average g ± standard deviation. a,bValues in the same column with different letters are significantly different.
Los resultados se expresan como media ± desviación estándar. a-bLos valores en la misma fila con diferentes letras son significativamente diferentes.
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initial decrease in the total microbiota, which after a period
in which it was below that of control subjects experienced
an increase.
It is an accepted fact that a large amount of bacteria per
gram in the colon is related to a better state of health
(Abdou, Zhu, Baker, & Baker, 2016). However, this is not
always the case, because as well as the quantity of bacteria,
the variety of species is also very important for human
health (Clemente et al., 2015; Singh, Yeon, & Vijay-Kumar,
2016). Consequently, if few species of bacteria are resistant
to an antibiotic, application of the same could eliminate the
flora sensitive to the antibiotic. As a consequence, a resistant
species can increase its number significantly and even
accommodate more units per gram, without this implying
any advantage for the host (Riley et al., 2013).
The Firmicutes phylum is usually the most frequent in the
GM of people in countries with Western-type diets (Panda
et al., 2014; Power, O´Toole, Stanton, Ross, & Fitzgerald,
2014); so, it is logical that it is the group that reaches higher
levels within the GM. Table 3 shows the results obtained
both in the control mice and in those exposed to the differ-
ent antibiotics, reaching in some cases values close to those
of the total microbiota, higher than 11 log CFU/g faeces. In
all cases, exposure to antibiotics caused a significant
increase in the Firmicutes population (P < 0.001). This
increase in the amount of Firmicutes per gram of colonic
content, and therefore in its relative proportion within the
GM, has previously been observed by other authors in stu-
dies in which experimental mice were exposed to different
types of antibiotics (Cho et al., 2012; Ellekilde et al., 2014;
Russell et al., 2015). However, this result was not always
consistent, since some authors have also found a decrease
in the amount of Firmicutes resulting from administration of
antibiotics (Vrieze et al., 2014). In general, increases in the
amount of Firmicutes are usually considered as an obeso-
genic factor (Arumugan et al., 2011).
With respect to the phylum Bacteroidetes, all antibiotics
used modified GM with respect to the control group, in the
case of ampicillin (P < 0.001), tetracycline (P < 0.001) and
sulphadiazine (P = 0.003), with a tendency to increase with
respect to the start of the experiment and to the control
group, as indicated in Table 3. When we compared this
increase in relation to that obtained for the Firmicutes
phylum, the results showed that in the control mice, the
tendency in the frame of diet, age and environment in
which the test was conducted favoured an increase of the
Bacteroidetes with respect to the Firmicutes. In fact, in the
control group, surprisingly, the proportion of Bacteroidetes in
GM was even higher than that of Firmicutes at week 16. In
contrast, in mice exposed to antibiotics, this tendency was
much less evident, and in any case, the proportion of
Bacteroidetes in the GM exceeded that of Firmicutes, as
occurred in the controls. The proportion of these two phyla,
expressed as Firmicutes to Bacteroidetes ratio, has been
described as higher in obese mice than in normoweight
mice, even in obese mice lacking leptin which plays a crucial
role in the regulation of appetite (Murphy et al., 2013;
Turnbaugh et al., 2009).
Table 3. Evolution of the faecal microbiota of the experimental control mice and with antibiotics in the feed for 16 weeks.
Day 0 Week 4 Week 8 Week 12 Week 16
All bacteria
Control 11.49 ± 0.01 11.47 ± 0.02 11.38 ± 0.10 11.41 ± 0.55 11.31 ± 0.11a
Ampicillin 11.58 ± 0.01 11.37 ± 0.01 11.26 ± 0.01 11.23 ± 0.02 11.70 ± 0.03b
Sulphadiazine 11.60 ± 0.02 11.39 ± 0.01 11.51 ± 0.02 11.68 ± 0.05 11.60 ± 0.09b
Tetracycline 11.35 ± 0.02 11.42 ± 0.02 11.30 ± 0.01 11.27 ± 0.02 11.49 ± 0.08b
Firmicutes
Control 10.69 ± 0.07 10.65 ± 0.06 10.41 ± 0.05 10.64 ± 0.11 10.49 ± 0.09a
Ampicillin 10.84 ± 0.07 10.40 ± 0.01 10.71 ± 0.01 10.84 ± 0.02 11.11 ± 0.01b
Sulphadiazine 10.55 ± 0.09 10.70 ± 0.01 11.00 ± 0.01 11.11 ± 0.03 11.00 ± 0.01b
Tetracycline 10.96 ± 0.02 10.76 ± 0.01 10.83 ± 0.01 11.30 ± 0.01 11.20 ± 0.01b
Bacteroidetes
Control 10.09 ± 0.04 10.57 ± 0.05 9.87 ± 0.07 10.68 ± 0.04 10.54 ± 0.04a
Ampicillin 10.48 ± 0.01 10.46 ± 0.01 10.28 ± 0.02 10.55 ± 0.09 10.87 ± 0.01b
Sulphadiazine 10.08 ± 0.03 10.49 ± 0.03 10.60 ± 0.02 10.89 ± 0.01 10.79 ± 0.02b,c
Tetracycline 10.40 ± 0.05 10.18 ± 0.04 10.30 ± 0.01 10.96 ± 0.00 11.00 ± 0.02c
Actinobacteria
Control 10.35 ± 0.04 9.50 ± 0.05 9.89 ± 0.07 9.86 ± 0.04 10.08 ± 0.04a
Ampicillin 10.67 ± 0.03 9.47 ± 0.02 9.38 ± 0.01 9.56 ± 0.09 9.89 ± 0.02a
Sulphadiazine 10.72 ± 0.02 9.62 ± 0.03 9.44 ± 0.02 9.86 ± 0.01 9.76 ± 0.01b
Tetracycline 10.40 ± 0.03 9.80 ± 0.02 9.95 ± 0.01 10.14 ± 0.03 9.90 ± 0.02a
Proteobacteria
Control 5.58 ± 0.06 5.35 ± 0.01 5.71 ± 0.04 6.84 ± 0.07 6.55 ± 0.05a
Ampicillin 5.70 ± 0.13 5.40 ± 0.33 6.26 ± 0.03 6.00 ± 0.23 7.38 ± 0.47b
Sulphadiazine 5.68 ± 0.09 6.24 ± 0.03 6.83 ± 0.04 6.05 ± 0.02 7.76 ± 0.03c
Tetracycline 5.45 ± 0.01 6.37 ± 0.02 5.62 ± 0.02 7.88 ± 0.03 7.64 ± 0.02b,c
Bifidobacterium
Control 5.54 ± 0.09 4.75 ± 0.08 5.49 ± 0.12 5.52 ± 0.11 5.42 ± 0.03a
Ampicillin 5.76 ± 0.06 4.63 ± 0.03 5.23 ± 0.04 5.24 ± 0.04 4.98 ± 0.02c
Sulphadiazine 5.96 ± 0.02 4.83 ± 0.11 5.09 ± 0.01 5.14 ± 0.02 4.75 ± 0.02c
Tetracycline 5.28 ± 0.12 4.88 ± 0.14 5.73 ± 0.03 5.73 ± 0.03 5.31 ± 0.05b
Lactobacillus
Control 9.07 ± 0.18 8.98 ± 0.08 8.34 ± 0.02 8.39 ± 0.11 8.43 ± 0.43a
Ampicillin 9.27 ± 0.21 8.09 ± 0.02 7.86 ± 0.04 8.06 ± 0.12 8.11 ± 0.03b
Sulphadiazine 9.32 ± 0.04 8.37 ± 0.02 8.28 ± 0.06 8.24 ± 0.03 8.14 ± 0.03a,b
Tetracycline 9.11 ± 0.02 8.71 ± 0.03 8.37 ± 0.02 8.38 ± 0.03 8.53 ± 0.02b
a–cEvolution of bacterial groups in the same column with different letters is significantly different.
a-b La evolución de los grupos bacterianos en la misma fila con diferentes letras son significativamente diferentes.
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With respect to the phylum Actinobacteria, the results
obtained can be found in Table 3. Only in the case of mice
exposed to sulphadiazine were Actinobacteria counts signif-
icantly different to those of control mice (P = 0.041), while
neither ampicillin nor tetracycline caused significant changes
in evolution with respect to control mice. This different
behaviour suggests different susceptibility on the part of
the bacteria that form the Actinobacteria phylum to the
antibiotics tested. Previous works related a greater presence
of this phylum in the GM of obese people (Arumugan et al.,
2011; Castro-Penalonga et al., 2018; Turnbaugh et al., 2009).
In the case of the phylum Proteobacteria, the results
obtained are represented in Table 3, reaching significant
increases (P < 0.001) for the treatment of the three antibiotics
used with respect to the control group. This increase is one of
the most important factors from the point of view of the
generation of dysbiosis, due to the ability of Proteobacteria
to cause low-grade inflammation in the large intestine,
because they can generate a large amount of toxins and
potentially toxic metabolites (Abdou et al., 2016; Morgan
et al., 2012). The result obtained is also consistent with the
fact that, as this phylum includes numerous pathogenic bac-
terial species, when they proliferate in the intestine, it is
necessary to use antibiotics to reduce or eliminate them
(Murphy et al., 2013). Perhaps for this reason, this phylum is
the one with the most resistance genes accumulated in GM
(around 35%) (Hu et al., 2013), even though in a normal
situation, it does not represent more than 2–3% of GM
(Caporaso et al., 2011). In fact, it is a common trend that in
studies in which mice are exposed to antibiotics, the
Proteobacteria phylum is one of the groups most affected,
producing very notable increases with in some cases reaching
up to 65 times the initial population (Leclercq et al., 2017).
The results obtained in relation to the amount of
Bifidobacterium per gram of faeces were lower than those
previously published by Okubo et al. (2013), who found
Bifidobacterium counts in faeces of the same strain of mice
in the range 8–10 log CFU/g. All antibiotics used in the trials
caused changes in the Bifidobacterium genus, reaching sig-
nificant differences (P < 0.001) in all three cases with respect
to the control group during the exposure time. Thus, in the
case of tetracycline, Bifidobacterium counts initially showed
higher values, which then eventually decreased, even below
those of the controls. However, in the case of both ampicillin
and sulphadiazine, antibiotic exposure caused more pro-
nounced decreases in the amount of Bifidobacterium in the
GM of the mice.
The human health benefits of a large amount of
Bifidobacterium have already been amply documented
(Georgieva et al., 2015; Gueimonde, Sánchez, De Los Reyes-
Gavilán, & Margolles, 2013). Therefore, the decreases experi-
enced in mice exposed to ampicillin and sulphadiazine reflect
changes that are detrimental to the host. The results obtained
are compatible with previously published data, such as those
of Gueimonde et al. (2013), who showed that many different
strains of Bifidobacterium usually used as probiotics are sensi-
tive to very small concentrations of β-lactams, whereas in the
case of tetracyclines, many tet genes are commonly found in
this genus, which confers intrinsic resistance (Gueimonde
et al., 2013). These results were also confirmed by other
studies in which the level of resistance of Bifidobacterium
strains commonly used as probiotics to different types of
antibiotics was verified (Georgieva et al., 2015; Moubareck,
Gavini, Vaugien, Butel, & Doucet-Populaire, 2005). According
to these authors, in all the cases tested, the strains of
Bifidobacterium were found to be sensitive to ampicillin
(hence the clear decrease in the counts of the mice exposed
to this antibiotic), while some strains show total or intermedi-
ate resistance to tetracycline.
In the case of the genus Lactobacillus spp., the counts
obtained in the control mice were compatible with those
previously published by Okubo et al. (2013), who found
faecal counts ranging from 8.5 to 10 log CFU/g. It is also
normal that Lactobacillus counts in mice are superior to
those that can usually be found in human faeces (Nguyen,
Vieira-Silva, Liston, & Raes, 2015). The antibiotics ampicillin
and tetracycline modified the GM showing significant
decreases with respect to control mice (P < 0.001). On the
contrary, sulphadiazine exposure did not cause any signifi-
cant change with respect to the control group. As in the case
of Bifidobacterium, this bacterial genus is considered bene-
ficial for health and is also commonly used as a probiotic
(Georgieva et al., 2015), although in some cases, a signifi-
cantly higher level of Lactobacillus was found in obese
patients than in thin subjects (Arumugan et al., 2011).
The exposure of the mouse GM to the different types of
antimicrobials showed different results, since no significant
effect was found in the case of exposure to tetracycline and
sulphadiazine, while exposure to ampicillin caused a clear
decrease in the population of Lactobacillus spp. This result is
reasonable taking into account that many strains of
Lactobacillus spp. are sensitive to ampicillin (Georgieva et al.,
2015). Other previous studies showed that both ampicillin
and other β-lactams decreased the counts of Lactobacillus
spp. in GM, even at very small doses (Leclercq et al., 2017).
However, this does not occur with all antibiotics since, for
example, Thuny et al. (2010) found an increase in the popula-
tion of Lactobacillus subsequent to the administration of a
vancomycin–gentamicin combination. This is related to the
use of vancomycin in some countries as a growth promoter in
animals. Other previous work (Temmerman, Pot, Huys, &
Swings, 2003) found that about 30% of the strains of
Lactobacillus studied were resistant to tetracycline. Perhaps
for this reason, the effects of tetracycline in this study were
not as clear or categorical as those of ampicillin.
Conclusion
The roles of microbiota in human health and interference
with GM by antibiotics are widely documented. This study
has demonstrated that even at low concentrations allowed
by European Union Regulation 37/2010, antibiotics can
affect GM. In global terms, all antibiotics employed caused
a marked reduction in total microbiota, but this reduction
was not homogeneous in the different bacterial groups
investigated. Thus, the maintenance or even increase in
microbial load of Firmicutes or Proteobacteria suggests
that eviction of microorganisms sensitive to these groups
of antibiotics provides space for resistant strains to overgrow
and dominate the niche. Therefore, the systematic use of
these antibiotics could reshape the microbiota and create an
obesogenic microbiota in the long-term and, as a conse-
quence, create a major problem afflicting global health.
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